
CRBP Stock Forecast & Price Target
CRBP Analyst Ratings
Bulls say
Corbus Pharmaceuticals is viewed favorably because its pipeline offers two differentiated shots on goal in large, underpenetrated markets: CRB-701 could address Nectin-4 solid tumors with early signals of improved safety versus Padcev, while CRB-913 showed 5% placebo-adjusted weight loss at 12 weeks with generally mild GI and psychiatric events. The company’s negative EV appears unwarranted given the registrational progress in TEMPO-1 for 2L OPSCC, the prospect of additional 1Q27 data for CRB-701 plus pembrolizumab, and the possibility that even niche adoption in obesity could support meaningful revenue. Although it remains non-revenue-generating with speculative risk and financing uncertainty, its clinical validation milestones and broad commercial optionality make the current valuation look overly discounted relative to the opportunity.
Bears say
Corbus Pharmaceuticals is viewed negatively because its valuation hinges on CRB-701 and CRB-913, both of which face meaningful clinical risk, including the possibility that efficacy proves insufficient or safety signals halt development. As a clinical-stage biotech with no revenues, it also depends on continued financing of ongoing R&D, while setbacks in regulatory approval, manufacturing, or commercialization could further pressure the business. The downside case even assumes shares could trade to $3.00 based on projected cash on hand 1 year from now, underscoring limited margin of safety if trials disappoint.
This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.
CRBP Analyst Forecast & Price Prediction
Start investing in CRBP
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast
CRBP Analyst Forecast & Price Prediction
Start investing in CRBP
Order type
Buy in
Order amount
Est. shares
0 shares